Saliva as an Alternative Matrix for Pharmacokinetic Research and Therapeutic Drug Monitoring of the Antituberculosis Drug Pyrazinamide
Antibiotics · 03.02.2026 · 15 (2) · 163
DOI: 10.3390/antibiotics15020163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 03.02.2026. Verfasst von Arnold J Ndaro und 6 weiteren Autor:innen. Beteiligte Einrichtung: Kilimanjaro Clinical Research Institute, Kilimanjaro Christian Medical Centre, Moshi P.O. Box 2236, Tanzania. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the DELTAS Africa Initiative.
Abstract (Originalsprache)
Introduction
Plasma is the standard biological fluid used in pharmacokinetic (PK) studies and therapeutic drug monitoring (TDM) of pyrazinamide, a key antituberculosis (TB) drug. This study described the PK of pyrazinamide in saliva and investigated whether saliva could serve as an alternative matrix for pyrazinamide PK evaluations.
Methods
Fifteen adult Tanzanian TB patients in the intensive treatment phase participated in a descriptive PK study. Time-matched saliva (stimulated using a Salivette® with citric acid) and plasma samples were collected at multiple intervals up to 24 h after drug intake. Pyrazinamide concentrations were measured using validated HPLC methods, exposure measures were assessed, and predictive performance for salivary concentrations was determined.
Results
Salivary exposure to pyrazinamide (AUC0–24h: 230 h·mg/L; Cmax: 28.6 mg/L) was lower than plasma exposure (AUC0–24h: 377 h·mg/L; Cmax: 36.4 mg/L, p < 0.001), but Tmax was similar (median 2.0 h, p = 0.893). A saliva/plasma ratio of 0.59 was assessed, and a reciprocal conversion factor of 1.68 allowed for reasonably accurate (bias 5.8%) but imprecise (imprecision 24.3%) plasma concentration predictions from saliva. Use of a conversion factor of 1.49, based on more stable saliva/plasma concentration ratios for samples between 2 and 6 h post-dose, resulted in a bias of 0.74% and imprecision of 17.7% for predicting plasma concentrations from salivary concentrations in the 2–6 h interval.
Conclusions
The exposure to pyrazinamide in saliva is relatively high. Salivary measurement of pyrazinamide can be used as a semi-quantitative predictor of pyrazinamide plasma concentrations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Kilimanjaro Clinical Research Institute, Kilimanjaro Christian Medical Centre, Moshi P.O. Box 2236, Tanzania.
- Department of Pharmacy, Pharmacology and Toxicology, Radboud Institute for Medical Innovation, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
- School of Pharmacy, KCMC University, Moshi P.O. Box 2240, Tanzania.
- Regional Commissioner's Office, Lindi P.O. Box 94, Tanzania.
- Department of Clinical Pharmacy, Rijnstate Hospital, 6815 AD Arnhem, The Netherlands.
ORCID-Profile: Rob E Aarnoutse
Förderung
- the DELTAS Africa Initiative
Zitieren
APA
Ndaro, A. J., Semvua, H. H., Mtabho, C. M., Heijens, C. A. W., Te Brake, L. H. M., Kibiki, G. S., & Aarnoutse, R. E. (2026). Saliva as an Alternative Matrix for Pharmacokinetic Research and Therapeutic Drug Monitoring of the Antituberculosis Drug Pyrazinamide. Antibiotics, 15(2), 163. https://doi.org/10.3390/antibiotics15020163
Vancouver
Ndaro AJ, Semvua HH, Mtabho CM, Heijens CAW, Te Brake LHM, Kibiki GS, et al. Saliva as an Alternative Matrix for Pharmacokinetic Research and Therapeutic Drug Monitoring of the Antituberculosis Drug Pyrazinamide. Antibiotics. 2026;15(2):163. doi:10.3390/antibiotics15020163
BibTeX
@article{Ndaro2026,
author = {Ndaro, Arnold J and Semvua, Hadija H and Mtabho, Charles M and Heijens, Claudia A W and Te Brake, Lindsey H M and Kibiki, Gibson S and Aarnoutse, Rob E},
title = {Saliva as an Alternative Matrix for Pharmacokinetic Research and Therapeutic Drug Monitoring of the Antituberculosis Drug Pyrazinamide},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {2},
pages = {163},
doi = {10.3390/antibiotics15020163}
}
EUVIMED